type 2 diabetes complicated with dyslipidemia
Conditions
Interventions
Administration of ezetimibe 10mg in the first 3 to 4 months, after one week wash out period, followed by the administration of pravastatin 10mg.
Administration of pravastatin 10mg in the first 3 to 4
Sponsors
Department of Endocrinology and Metabolism Kyoto Prefectural University of Medicine, Graduate School of Medical Science
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with type 2 diabetes complicated with dyslipidemia (not taking medication for hyperlipidemia, 120 mg / dl =< LDL in the serum lipid-C < 160 mg / dl, meets TG >= 150 mg / dl)
Exclusion criteria
Exclusion criteria: 1)Patients with hypersensitivity against ezetimibe and pravastatin, 2)Patients with severe renal dysfunction and severe hepatic dysfunction, 3)Pregnant women, women who may be pregnant, and breast-feeding women. 4)Patients with drug-induced and familial dyslipidemia, 5)Patients treated with insulin 6)Patients judged by the investigator/ sub investigator to be ineligible for some other reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change and percent change in TC, LDL-C, HDL-C, TG, Remnant like particle cholesterol (RLP-C), small dense LDL and FFA. Change and percent change in HbA1c and insulin | — |
Countries
Japan
Outcome results
None listed